Background: Conjunctival melanoma (CM) is a rare, invasive tumor in the eye that readily metastasizes and spreads. Based on some significant clinicopathological information, we aimed to develop a prognostic model to predict the overall survival (OS) of CM patients.
Methods: Data of patients diagnosed with CM from 2000 to 2019 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Significant prognostic factors were extracted and integrated based on competing risk regression to build a nomogram. Harrell's concordance index (C-index), receiver operating characteristic (ROC) curve, and calibration plots were used to evaluate the performance of the nomogram.
Results: The study included 272 patients with CM, with a median age of 63 years. A nomogram was developed using age and tumor-node-metastasis (TNM) stage as variables. The model's C-index was 0.755, and the area under the curve (AUC) was 0.774, 0.812, and 0.815 at 5, 8, and 10 years, respectively. The calibration plot used to predict CM demonstrated good consistency between the predicted OS probability and the actual OS probability.
Conclusions: We have developed a nomogram model to predict the OS of patients with CM, which can predict the survival of these patients. The model's prognostic value is higher than that of the American Joint Committee on Cancer (AJCC) staging system alone. This tool can help evaluate the tumor-specific prognosis, identify patients at high risk of cancer-specific death, and guide clinical decision-making.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928613 | PMC |
| http://dx.doi.org/10.21037/tcr-23-1277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
National early warning score 2 plus non-invasive capnography and perfusion index to estimate poor outcomes in emergency departments.
Am J Emerg Med
January 2025
Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain; Emergency Department, Hospital Clínico Universitario, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
Background: The study of the inclusion of new variables in already existing early warning scores is a growing field. The aim of this work was to determine how capnometry measurements, in the form of end-tidal CO2 (ETCO2) and the perfusion index (PI), could improve the National Early Warning Score (NEWS2).
Methods: A secondary, prospective, multicenter, cohort study was undertaken in adult patients with unselected acute diseases who needed continuous monitoring in the emergency department (ED), involving two tertiary hospitals in Spain from October 1, 2022, to June 30, 2023.
Identification and validation of soft tissue sarcoma-specific transcriptomic model for predicting radioresistance.
Int J Radiat Biol
January 2025
Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Purpose: We aimed to identify the transcriptomic signatures of soft tissue sarcoma (STS) related to radioresistance and establish a model to predict radioresistance.
Materials And Methods: Nine STS cell lines were cultured. Adenosine triphosphate-based viability was determined 5 days after irradiation with 8 Gy of X-rays in a single fraction.
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Blood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFPatients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.
View Article and Find Full Text PDFThe efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.
PLoS One
January 2025
Center of Excellence in Probiotics, Srinakharinwirot University, Bangkok, Thailand.
Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-eight participants with risk factors of metabolic syndrome according to the inclusion criteria were randomized into two groups and given probiotics (Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1) (n = 31) or a placebo (n = 27).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!